Ibandronic acid injections 1 mg/ml. 3 ml. vial №1

Description

Ibandronic 3 ml Composition
active substance: ibandronic acid;

1 ml of concentrate contains ibandronic acid (in the form of sodium ibandronate monohydrate) 1 mg

excipients: sodium chloride, glacial acetic acid, sodium acetate trihydrate, water for injection.

Ibandronic 3 ml Indications.
Prevention of skeletal injuries (pathological fractures, damage to bone tissue, requiring radiation therapy or surgical treatment) in patients with breast cancer and metastatic bone tissue.

Treatment of hypercalcemia in malignant neoplasms with or without metastases.

Ibandronic 3 ml Contraindications
Hypersensitivity to ibandronic acid or to any other component of the drug. Hypocalcemia (see section “Peculiarities of use”).

Method of administration and dosage.
dosage
For the treatment of osteoporosis, the recommended dose is 3 mg ibandronic acid as an intravenous injection of 15-30 seconds duration every 3 months. The drug is intended only for intravenous administration (see “Peculiarities of use”).
Patients need to additionally take calcium and vitamin D (see Sections “Peculiarities of use”, “Interaction with other medicinal products and other types of interactions”).
If the planned dose is missed, the injection of the drug should be given as soon as possible. In the future, injections should be done every 3 months since the last injection of the drug.
The optimal duration of bisphosphonate treatment for osteoporosis has not been established. With an individual approach to the patient, the need to continue treatment with ibandronic acid should be periodically reviewed, taking into account the benefits and potential risks, especially after 5 or more years of using the drug.

Children.
The safety and efficacy of ibandronic acid in children (under the age of 18) have not been established.